RBC Capital Downgrades Design Therapeutics to Sector Perform, Lowers Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Leonid Timashev has downgraded Design Therapeutics (NASDAQ:DSGN) from Outperform to Sector Perform and lowered the price target from $23 to $7.
August 15, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Design Therapeutics has been downgraded by RBC Capital from Outperform to Sector Perform, with a lowered price target from $23 to $7.
The downgrade from Outperform to Sector Perform by RBC Capital indicates a less optimistic outlook for Design Therapeutics. The significant reduction in the price target from $23 to $7 suggests that the analyst believes the stock is overvalued at its current price. This could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100